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Abstract: The major virulence factors of Clostridium difficile infection (CDI) are two 
large exotoxins A (TcdA) and B (TcdB). However, our understanding of the specific roles 
of these toxins in CDI is still evolving. It is now accepted that both toxins are enterotoxic 
and proinflammatory in the human intestine. Both purified TcdA and TcdB are capable of 
inducing the pathophysiology of CDI, although most studies have focused on TcdA. 
C. difficile toxins exert a wide array of biological activities by acting directly on intestinal 
epithelial cells. Alternatively, the toxins may target immune cells and neurons once the 
intestinal epithelial barrier is disrupted. The toxins may also act indirectly by stimulating 
cells to produce chemokines, proinflammatory cytokines, neuropeptides and other 
neuroimmune signals. This review considers the mechanisms of TcdA- and TcdB-induced 
enterotoxicity, and recent developments in this field. 
Keywords: Clostridium difficile; toxin A (TcdA); toxin B (TcdB); enterotoxicity 
 
1. Introduction  
Clostridium difficile is a Gram-positive, spore-forming anaerobic bacillus. It is the most common 
cause of nosocomial antibiotic-associated diarrhea and is the etiologic agent of pseudomembranous 
colitis [1]. With the recent emergence of hypervirulent strains, the incidence of C. difficile-associated 
diarrhea and intestinal inflammatory disease (collectively designated CDI) has increased significantly 
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in both North America and Europe, causing lengthy hospitalization, substantial morbidity and mortality. 
Of further concern is the recent emergence of hypervirulent strains that are resistant to antibiotics. 
CDI is a toxin-mediated disease. Two exotoxins, toxin A (TcdA) and toxin B (TcdB), are the most 
extensively studied major virulence factors, supported by reports demonstrating that C. difficile 
clinical isolates lacking both toxin genes are non-pathogenic in humans and animals [2–4]. In addition 
to TcdA and TcdB, a limited number of C. difficile isolates also produce a binary toxin (CDT) that 
exhibits ADP-ribosyltransferase activity [5–7]. The pathophysiological role of CDT in CDI remains 
poorly understood [8–10]. In addition to these toxins, several other factors may play a role in disease 
manifestation. These factors include fimbriae and other molecules facilitating adhesion, capsule 
production and hydrolytic enzyme secretion, although none of these have been studied in detail [11–13]. 
Recent studies have also shown that the surface layer proteins of C. difficile play an important role in 
bacterial colonization, and that antibodies raised against these proteins are partially protective [14,15]. 
TcdA and TcdB possess a wide spectrum of biological activities, which may contribute to the range 
of symptoms associated with CDI. Toxin-induced disruption of the cytoskeleton leads to cytopathic 
effects in cultured cells within hours of intoxication, and this effect has been suggested to be mediated 
through Rac1 inactivation [16]. Although TcdB is generally more potent (~1000 fold) than TcdA, both 
are cytotoxic to most cultured cells where they trigger caspase-dependent apoptosis [17–19]. TcdA and 
TcdB also possess potent proinflammatory activity, and are capable of stimulating intestinal epithelial 
cells and immune cells to produce cytokines and chemokines [20–24]. Ileal-loop experiments in 
animal models have clearly demonstrated that TcdA is an enterotoxin [25,26]. TcdB was initially 
reported to exhibit no enterotoxic activity in animal models [27,28]. However, later studies have 
demonstrated its enterotoxic and proinflammatory activities in human colonic biopsies [29], human 
intestinal xenografts in immunodeficient (SCID) mice [20], and in hamsters [30]. To support this view, 
TcdA
−B
+ C. difficile clinical isolates can cause disease in patients and in experimental animal models 
[30,31]. Both TcdA and TcdB are highly toxic when administered systemically [32,33]. Systemic 
toxemia may therefore contribute to extraintestinal disease complications associated with severe cases 
of CDI [34,35]. In this review, we highlight the mechanisms of TcdA- and TcdB-induced 
enterotoxicity, and consider recent developments in this area. 
2. C. difficile Infection in Humans 
C. difficile infection is caused by the ingestion of vegetative organisms and spores, most likely the 
latter which survive exposure to gastric acidity and germinate in the colon [36,37]. Antibiotic exposure 
is the most significant risk factor in  developing CDI [38]. The clinical manifestations are highly 
variable, ranging from asymptomatic carriage, to mild self-limited diarrhea, to severe 
pseudomembranous colitis (collectively designated as CDI). Systemic complications are rare, but have 
been reported [39–43]. Standard therapy depends on treatment with vancomycin and/or metronidazole, 
neither of which is fully effective [44]. More importantly, an estimated 15–35% of those infected with 
C. difficile relapse following treatment [45,46]. Alternative experimental treatment options include the 
use of probiotics, fecal treansplant, toxin-absorbing polymer, new antibiotics, monoclonal antibodies, 
IVIG, and toxoid vaccines [47–52].  Toxins 2010, 2  
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C. difficile infection accounts for approximately 15–25% of cases of antibiotic-associated diarrhea, 
and the incidence of infection is rising steadily [53]. Several recent hospital outbreaks of CDI in North 
America, associated with high morbidity and mortality rates, have been attributed to the widespread 
use of broad-spectrum antibiotics. The emergence of new and more highly virulent strains of 
C. difficile has also contributed to the increased incidence and severity of the disease [54,55].  
Asymptomatic carriage of C. difficile in infants is estimated to be approximately 50% or higher [56]. 
These infants can have high numbers of toxigenic C. difficile and high levels of toxins in their stools 
without showing symptoms [57–61]. It is unclear why such infants are usually refractory to CDI, even 
though they carry high numbers of the organism and toxins. Fetal intestinal epithelial cells were 
reported to be much less sensitive to intoxication than adult cells, and this may contribute to this 
asymptomatic carriage [62]. Another hypothesis is that infants may lack the membrane receptors 
required for toxin binding. Alternatively, these receptors may be masked by a thicker layer of mucus in 
infants, supported by the observation that mucins directly inactivate C. difficile toxins [63]. 
3. Animal Models of CDI 
In vivo animal infection modes for CDI have been established using a number of animal species, 
including hamsters, guinea pigs, rabbits, germfree mice and rats, but most of the work has been done 
in hamsters [64–73]. The disease in hamsters can be induced by a variety of antibiotics, and the 
intestinal damage is mainly localized to the cecum, with some involvement of the ileum. Infected 
hamsters develop fulminant diarrhea and die rapidly from severe enterocolitis. Lung damage has also 
been reported in hamsters [28]. Because of this fulminant disease course, the hamster model does not 
accurately recapitulate the disease course and progression in humans. Chen and colleagues recently 
developed a conventional mouse model of CDI, in which the primary injury site is the colon. 
Moreover, the disease progression follows a similar pattern to human CDI [74]. Our group has also 
recently established a piglet model of acute and chronic C. difficile infection, which mimics many of 
the key characteristics observed in human CDI [35]. Interestingly, in other less well defined animal 
models, TcdB was reported to cause damage and edema in cardiac tissue of zebrafish embryos [28,32], 
and severe jejunal lesions in rabbits [75]. 
In animal models, an unusual observation with C. difficile infections is that infant hamsters are 
insensitive to C. difficile infection [76,77], a phenomenon that is also seen in human infants. By 
contrast, neonatal gnotobiotic piglets are highly sensitive to C. difficile infection [35].  
Studies in animal models have contributed greatly to our understanding of the pathogenicity of 
TcdA and TcdB. It was speculated that TcdA was the most important component in disease production 
because it elicits extensive tissue damage and fluid accumulation in several animal models [28,78–80]. 
Moreover, some reports showed that immunization with TcdA induces full protection in rabbits [81], 
hamsters [82] and gnotobiotic mice [83] against C. difficile infection. Serum TcdA and TcdB titers 
also correlate with disease activity in CDI patients [84–86]. In contrast, TcdB does not exhibit 
enterotoxicity in rabbit ileal and colonic loops [78], hamster ileal loops [87] or in mouse ileal loops 
[88] even though it is a more potent cytotoxin than TcdA [89]. However, ex vivo studies using 
human colonic explants showed that TcdB is more potent than TcdA in inducing epithelial barrier 
damage and proinflammatory cytokines signaling, consistent with enterotoxicity [29]. We have Toxins 2010, 2  
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confirmed this finding in vivo in a human intestinal xenograft model [20]. In support of this, 
TcdA
−TcdB
+ strains are known to cause human CDI, with a full spectrum of disease manifestations 
[90]. TcdA
−TcdB
+ strains can also cause disease in rabbit, hamster and mouse models [91–93]. More 
recently, Lyras et al. generated isogenic C. difficile (strain 630) in which the tcdA or tcdB gene is 
insertionally inactivated. In this study, the isogenic strains with only intact tcdB gene, but not tcdA, 
caused CDI in hamsters [30]. Taken together, it is believed that both TcdA and TcdB are enterotoxic 
and responsible for the full spectrum of symptoms in CDI. Consistent with this view, several studies 
have shown that antibodies against both TcdA and TcdB are necessary to protect hamsters from 
CDI [94,95].  
Why TcdB does not show enterotoxicity in ileal loops of animal models, while TcdA
−TcdB
+ 
C. difficile strains are able to cause disease in the same animals is still unknown. It was reported that 
hamster and rabbit intestine possess specific TcdA brush border receptors [96,97], while receptors for 
TcdB have not yet been identified. One assumption is that TcdB receptors do not exist in rodent small 
intestine, but might be located in the colon or cecum. Alternatively, TcdB could be chaperoned by 
another as yet unknown bacteria-derived protein, although, purified TcdB has been shown to cause 
histological damage in hamster caeca [87,98]. Moreover, the disease in hamsters is localized in the 
cecum with some involvement of ileum. Ironically, even though the disease in mice and rats involves 
in colon [74,77], most of the gut-loop experiments have been carried out using ileum segments. 
Therefore, intestinal activities of TcdB in animal models should be carefully interpreted and studies 
testing TcdB enterotoxicity in cacecal loops of rabbits or colonic loops of mice are urgently needed. 
Secondly, using transwell system TcdB has been indicated to preferably bind to basal surface of 
epithelial monolayers [99]. Therefore, TcdB receptors may not be exposed apically to the gut lumen. 
Once the epithelial barrier is impaired by other factors, TcdB may gain access to its “receptors”, 
leading to intestinal inflammation. In support of this view, it was reported that when given 
intragastrically to hamsters, TcdB did not cause any disease unless the intestine is first breached either 
by TcdA or by manipulation [80].  
4. Mechanism of Action and Functional Domains of TcdA and TcdB 
4.1. Structure of TcdA and TcdB  
TcdA (308 kDa) and TcdB (269 kDa) belong to the Clostridial glucosylating toxins family, and 
share high amino acid sequence identity [100]. They are structurally similar to each other [89], 
including an N-terminal glucosyltransferase domain (GT), the newly identified autocatalytic cysteine 
proteinase domain (CPD), the central translocation domain (TMD) covering a hydrophobic region 
(HR), and the C-terminal receptor binding domain (RBD) consisting of clostridial repetitive 
oligopeptides (CROPs) [101] (Figure 1). Recently, 3D structures of two RBD fragments of TcdA, 
CPD of TcdA, and the catalytic domain (residues 1–543) of TcdB have been solved [102–105]. 
However, due to their unusual sizes and linear domain arrangement the high-resolution structures of 
holotoxins have not been determined. Most recently a group of scientists used small-angle X-ray 
scattering (SAXS) methods to obtain low-resolution structure/model of native TcdB [106]. The 
structure showed a monomeric shape of TcdB in solution. They modeled the structures of individual 
domains onto the SAXS structure of TcdB and obtained its 3D structure, which shows four distinct Toxins 2010, 2  
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structure domains separating from each other. Structures of GT, CPD and TMD can be aligned within 
three domains of the SAXS structure, but the TMD appears as a large solvent-exposed protrusion [106]. 
Figure 1. Structure of TcdA and TcdB. TcdA and TcdB consist of four domains: an 
N-terminal glucosylatransferase domain (GT), an autocatalytic cysteine protease domain 
(CPD), a central translocation domain (TMD) covering a hydrophobic region (HR), and a 
C-terminal receptor binding domain (RBD) consisting of clostridial repetitive 
oligopeptides (CROPs). The DXD (Asp-X-Asp) motif and a conserved trytophan present 
in the GT domain are involved in Mn
2+ and UDP-glucose binding. The conserved DHC 
(Asp-His-Cys) catalytic triad in the CPD domain mediates toxin autocleavage. The DXG 
(Asp-X-Gly) motif in the TMD region of TcdB was reported to possess aspartate protease 
activity, which could be involved in toxin cleavage. 
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4.2. The C-terminal receptor binding domain (RBD) mediates receptor binding  
The most striking feature of the RBDs of TcdA and TcdB is the presence of CROPs of 21-, 30-, or 
50-amino acid residues. Different approaches to analyzing the sequence of CROPS of TcdA reveal that 
this region contains between 30 and 38 contiguous repeats, whereas in TcdB those appear to be 
between 19 and 24 residues [102,103]. CROPs may play a putative role in initial target cell interaction 
and receptor binding. Recently, two RBD fragments (terminal 127 and 255 residues) of TcdA were 
crystallized [102,103]. These studies showed that TcdA folds in a solenoid-like structure, which is 
suggested to increase the surface area of proteins and enable protein-protein or protein-carbohydrate 
interactions. It was previously showed that TcdA binds to the trisaccharide Galα1-3Galβ1-4GlcNAc 
[107], carbohydrate antigens like Lex and Ley [108], components in human milk and carbohydrates 
from brush border membranes of hamster ileum [109]. Interaction of TcdA with glycosphingolipids 
has been suggested as well [110]. Recently, the crystal structure of TcdA was solved in complex with a 
synthetic carbohydrate consisting of Galα1-3Galβ1-4GlcNAc structure [103]. However, human do not 
have a functional α-galactosyltransferase and, therefore, cannot form α-galactosyl bonds, indicating 
that the carbohydrate structure Galα1-3Galβ1-4GlcNAc cannot be part of intestinal receptors in human 
[111,112]. Therefore the disaccharide Galβ1-4GlcNAc, which is present in humans, has been 
suggested to be part of a possible receptor. Until recently, it was reported that glycoprotein 96 (gp96) 
is a human colonocyte plasma membrane binding protein for TcdA [113]. Our understanding on the 
TcdB receptor is even more limited. Published data indicate that TcdA and TcdB use different types of 
receptors. The receptor for TcdB appears to be basolateral, whereas the TcdA receptor is on the apical 
sites [114]. Toxins 2010, 2  
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4.3. The central translocation domain (TMD), autocatalytic cysteine proteinase domain (CPD) and 
uptake of TcdA and TcdB  
The putative TMD makes up more than 50% of the total size of the toxins and contains a 
hydrophobic region which is most probably responsible for membrane insertion. To date, little is 
known about exact functions of the TMD. However, recently it was suggested that the Asp-Xaa-Gly 
(DXG) motif of TcdB possesses aspartate protease activity, which could be involved in toxin   
cleavage [115]. 
The newly identified CPD domain is located between the GT and TMD domains, starting from 
residue 543 to residue 767 in TcdB. The CPD domain contains a conserved catalytic triad   
(Asp587-His653-Cys698) of a cysteine protease and mediates toxin autocleavage. Interaction between 
the RBD and the host cell receptors is believed to initiate receptor-mediated endocytosis 
[108,116,117]. Although the intracellular mode of action remains unclear, it has been proposed that the 
toxins undergo a conformational change triggered by the low pH environment of  the endosomal 
compartment, leading to a membrane insertion and channel formation [118–121]. A host cofactor, 
inositol hexakisphosphate (InsP6), is thought to be the cofactor to trigger CPD-mediated autocatalytic 
cleavage of the toxins, and the subsequent release of the N-terminus GT domain into the cytosol [115]. 
4.4. N-terminal glucosylatransferase domain (GT)  
The N terminus (residues 1–543) harbors the glucosyltransferase activity of the toxins and is the 
biologically activity domain. The crystal structure of the GT domain of TcdB revealed a set of 
essential amino acid residues involved in glucosyltransferase reaction or substrate binding [104]. The  
Asp-Xaa-Asp (DXD) motif and a conserved tryptophan are involved in Mn
2+ and UDP-glucose 
binding. In addition to the DXD motif, several other residues are also essential for enzyme activity [122]. 
4.5. Small GTPase proteins as targets of TcdA and TcdB 
The common features of small GTPases include their small molecular mass (18–28 kDa), their  
C-terminal polyisoprenylation, and their property of binding to guanine nucleotides. They are 
molecular relays, which transmit signals when bound to GTP and stop doing so when bound to GDP. 
Small GTPases are subdivided into the subfamilies of Ras, Rho, Rab, Arf, and Ran. Rho subfamily 
members also called Rho GTPases or Rho proteins are major known intracellular targets of TcdA and 
TcdB. Approximately 20 Rho GTPases have been described, including RhoA, Rac1 and Cdc42 [100].  
Once in the cytosol, the GT effector domain of the toxins mono-O glucosylates low molecular 
weight GTPases of the Rho family, including RhoA, Rac1, and CDC42 [123]. Rho GTPases are 
inactive in the GDP-bound form and associated with guanine nucleotide dissociation inhibitors (GDI), 
which keep the GTPases in the cytosol. Guanine nucleotide exchange factors (GEFs) activate Rho 
GTPases, enabling interaction with different effectors to control numerous signaling processes. The 
active state of Rho GTPase is terminated by hydrolysis of bound GTP facilitated by GTPase-activating 
proteins (GAP). Rho GTPases regulate many host cell functions including epithelial barrier functions, 
immune cell migration, adhesion, phagocytosis, cytosecretion and immune cell signaling [100,101]. 
Glucosylation of Rho proteins inhibits their “molecular switch” function, thus blocking Rho   Toxins 2010, 2  
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GTPase-dependent signaling. This leads to alterations in the actin cytoskeleton, loss of tight junction 
integrity, massive fluid secretion, acute inflammation and necrosis of the colonic mucosa [26,123,124]. 
In addition to TcdB and TcdA from the prototype strain VPI-10463, toxin variants of   
C. difficile toxin B, TcdB-1470 and TcdB-8864, have been isolated from TcdA-negative strains 
[125,126]. These variants have been reported to produce a somehow different cytopathic effect (CPE) 
than the classical neurite-like morphology induced in fibroblasts by TcdB-10463. TcdB-1470 was 
shown to be a functional hybrid possessing the receptor-binding and internalization domain of   
TcdB-10463 and the glucosyltransferase domain of C. sordellii TcsL. TcdB-1470 does not glucosylate 
RhoA but predominantly modifies Rac1 from Rho subfamily and also members of the Ras subfamily 
(Ras, Rap, Ral). TcdB-8864 has also altered glucosylation specificity and recognizes Rac1, Rap2 and 
Ra1. Another variant TcdB, TcdB-C34 has substrate specificity on Rho, Rac and Cdc42 from Rho 
subfamily and Ras, Ral, and Rap from Ras subfamily [100,127]. 
C. difficile is a very heterogenerous species. Currently, 24 variant toxinotypes are identified in 
addition to reference strain VPI 10463. The most-studied variant strains are TcdA
− TcdB
+ strains and 
binary toxin CDT-producing strains, which will be discussed below. Variant toxins show differences 
in size, antibody recognition, glucosylation of small GTPases and consequently in their effects on the 
cells [128]. 
4.6. C. difficile binary toxin (CDT) 
In addition to TcdA and TcdB, some C. difficile isolates (less than 10%), including the epidemic 
NAP1/027 strain (toxinotype III), produce a third toxin called C. difficile binary toxin (CDT) [129]. 
Most binary toxin-positive strains also produced
 TcdB and/or TcdA. However, they had significant 
changes in the
 tcdA and tcdB genes and belonged to variant toxinotypes III,
 IV, V, VII, IX, and XIII 
[129]. Strains that produce CDT but neither of the TcdA and TcdB have been recently described 
[9,130]. This toxin is a two-component ADP ribosyltransferase encoded by the genes cdtA (enzymatic 
component) and cdtB (binding component). CDT-positive isolates are cytopathic in cell culture. When 
tested in CDI animal models, TcdA
−TcdB
−CDT
+ strains cause fluid accumulation in rabbit ileal loops 
but no diarrhea or death in hamster models [9]. A more recent study showed CDT induces formation of 
microtubule-based protrusion and increases adherence of bacteria to intestinal epithelium [10]. 
Another exciting advancement is the determination of CDTa in complex with ADP ribose donors, 
NAD and NADPH [131]. This structure will have implications in understanding CDT recognition, and 
will be valuable for the rational design of therapeutic strategies. 
5. The Mechanisms Underlying the Enterotoxicity of TcdA and TcdB 
The clinical appearance of CDI is highly variable, ranging from mild self-limited diarrhea to severe 
pseudomembraneous colitis. The disease starts in the large bowel and shows distinguishing “volcanic 
eruption” characteristics of the pseudomembranous lesion observed in severe colitis. Diarrhea and 
colitis are two major clinic manifestations of CDI. In severe cases of CDI, patients present with 
systemic inflammatory syndromes that include abdominal pain, fever, hypotension, tachypnea, and 
leukocytosis. Most of these clinical presentations can be ascribed to direct intestine tissue damage and 
inflammation mediated by TcdA and TcdB. This section describes how TcdA and TcdB can induce Toxins 2010, 2  
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such intestinal damage and inflammation. The proinflammatory mediators involved in the 
enterotoxicity of TcdA and TcdB are summarized in Table 1. 
Table 1. Proinflammatory mediators involved in the enterotoxicity of TcdA and TcdB. 
Proinflammatory mediators   Sources (cells or tissue)  Known or proposed functions  References 
IL-8 Intestinal  epithelia, 
macrophages, peripheral 
blood monocytes  
Neutrophil recruitment  [21,23,132] 
GRO-α (growth-related 
oncogene) 
Intestinal epithelia  Neutrophil recruitment  [21,133] 
MIP-1 (macrophage 
inflammatory protein-1) 
Intestinal epithelia, 
macrophages 
Neutrophil recruitment  [133,134] 
MIP-2 (macrophage 
inflammatory protein-2) 
Intestinal epithelia, 
macrophages 
Neutrophil recruitment  [133,134] 
ENA-78 (epithelial neutrophil-
activating peptide-78) 
Intestinal epithelia  Neutrophil recruitment  [21,133] 
MCP-1 (monocytes-
chemotactic protein-1) 
Intestinal epithelia  Neutrophil recruitment  [21] 
ICAM-1 (intercellular 
adhesion molecule-1) 
Endothelial cells, 
neutrophils, epithelia 
Neutrophil adhesion to 
endothelial cells 
[135–137] 
IL-1 Macrophages,  dendritic 
cells, 
Neutrophil recruitment, 
enhancing IL-8 production,  
[135,136,138,139] 
IL-6  Monocytes, dendritic cells not  specified  [24] 
TNF-α  Macrophages, monocytes  Neutrophil recruitment  [24,138,139] 
IFN-γ  Neutrophils  Enhancing chemokine and 
ICAM-1 expression expression 
[134] 
LB4 (Leukotriene B4)   Macrophages, mast cells  Neutrophil recruitment, activation 
of transient receptor potential 
vailloid (TRPV1) and SP release 
[138,140,141] 
LC4 (Leukotriene C4)  Mast cells  Stimulation of fluid secretion by 
intestinal epithelia 
[140] 
RMCP II (rat mast cell 
protease II) 
Mast cells  Indicator of mast cell activation  [140] 
SP (substance P)  Intestinal neurons  Activation of mast cells and 
macrophages 
[142,143] 
CGRP (calcitonin gene-related 
peptide) 
Intestinal neurons  Activation of mast cells and 
macrophages 
[142,143] 
NT (neurotensin)  Intestinal neurons  Activation of mast cells  [144] 
VIP (vasoactive intestinal 
polypeptide) 
Colonic submucosal neurons  Activated partially via an IL-1β-
dependent pathway ( its role in 
the intestine is to increase motility 
[145] 
PAR2 (protease activated  
receptor 2) 
Enterocytes, neurons, 
endothelial cells, neutrophils 
Intestinal inflammation  [146] 
Inflammasome Macrophages  IL-1β production  [147] Toxins 2010, 2  
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Table 1. Cont. 
Proinflammatory mediators   Sources (cells or tissue)  Known or proposed functions  References 
Melanin-concentrating hormone 
(MCH) 
Intestinal tissue  Upregulation of IL-8 
transcription 
[148] 
Reactive oxygen species (ROS)  Neutrophils  Direct damage of proteins and 
lipids, induction of IL-8 and 
ICAM-1 
[149–152] 
Cyclooxygenase-2 (COX-2)  Human colonocyte, human 
intestinal xenograft 
Formation of PGE2  [150,153] 
Prostaglandin E2 (PGE2)  Human colonocyte, human 
intestinal xenograft 
Intestinal inflammation  [150] 
Phospholipase A2  Rabbit ileal tissue, human 
T-84 cells 
Synthesis of inflammatory lipid 
mediators 
[154] 
Platelet-activating factor (PAF)  Rabbit ileal tissue  Stimulation of fluid secretion by 
intestinal epithelial cells 
[155] 
Na+/H+ exchanger (NHE)  Intestinal epithelial cells  Involvement in Na+ absorption 
and fluid homeostasis 
[156] 
Angiotensin II (ANGII)  Rabbit ileal tissues  Regulation of intestinal 
secretion and absorption 
[157] 
Epidermal growth factor receptor 
(EGFR) 
Human colonic epithelial 
cells 
Activation of IL-8  [158] 
5.1. Disruption of the tight junctions of epithelial barriers 
The direct target tissue of the C. difficile toxins is the colonic epithelium. One of the most direct 
events attributed to TcdA and TcdB in the intestine is their ability to disrupt tight junctions and to 
breach the intestinal epithelial barrier [159]. Inactivation of Rho proteins by the toxins causes the loss 
of epithelial barrier function, since these small GTPases are critical regulators of tight junction 
function. TcdA and TcdB both catalyze the transfer of glucose from UDP-glucose to threonine-37 in 
RhoA and threonine-35 in Rac1 and Cdc42, inactivating these signaling proteins [160]. In human 
colonic epithelial cell lines and in human colonic explants, both toxins impair tight junction function 
resulting in a loss of electrical resistance and the peri-junctional actinomyosin ring, and an increased 
paracellular permeability from the luminal domain [29,161–164]. Increased blood-to-lumen 
permeability is also observed in vivo in rat and rabbit intestine exposed to TcdA [165,166]. This 
increase in paracellular permeability was reported to be Rho-independent, albeit via an unknown 
mechanism [167]. However, Teicher et al. found that treatment of Caco-2 cells with 
glucosyltransferase-deficient TcdA does not significantly induce decrease in transepithelial electrical
 
resistance (TER), strongly arguing for a critical role of Rho glucosylation in this process [168]. The 
enhanced mucosal permeability causes an array of consequences, including promoting access of 
neutrophils to the intestinal lumen as is seen in CDI patients. In addition to disruption of tight 
junctions, TcdA also causes detachment of epithelial cells in human colonic mucosal explants [29]. 
Adhesion of epithelial cells to the underlying matrix occurs by focal contact formation. More recently, 
Kim and colleagues described mechanisms on how TcdA induce detachment of epithelial cells [169]. Toxins 2010, 2  
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They found that TcdA binds colonocyte Src, causing dephosphorylation of the focal adhesion kinase 
(FAK) and paxillin, which is independent of the Rho glucosylation [169]. 
5.2. Apoptosis and necrosis of epithelial cells and other cell types 
The apoptogenic properties of TcdA and TcdB are well known, and they may contribute to the 
inflammatory process induced by these toxins. Treatment of intestinal epithelial cell lines with either 
TcdA or TcdB results in their apoptosis [18,19,132,170]. TcdA and TcdB induce both apoptosis and 
necrosis of epithelial cells in human intestinal xenografts in a chimeric mouse model [20]. TcdA also 
induced apoptosis in tissue cultures of human colonic biopsy specimens [132]. Moreover, TcdA and 
TcdB may gain access to the underlying lamina propria and submucosa, to act directly on other cell 
types once the epithelial barrier is breached. In fact, TcdA-induced apoptosis of monocytes and T cells 
is also reported [171,172]. 
Brito and his colleagues reported that TcdA-induced apoptosis of T84 cells is completely inhibited 
by blocking toxin enzymatic activity on Rho GTPases with uridine 5'-diphosphate-2',3'-dialdehyde, 
and is partially inhibited by caspase-1, -3, -6, -8, and -9 inhibitors [18]. Caspases 3, 6, 8, and 9, and 
Bid are activated following cellular intoxication. TcdA also induces changes in mitochondrial 
membrane potential and release of cytochrome c after 18-24 h of intoxication, a time course that is 
similar to caspase-9 activation. The authors concluded that TcdA induces apoptosis by a mechanism 
that depends on Rho-inactivation and the subsequent activation of caspases 3, 6, 8, and 9, as well as 
Bid and mitochondrial damage followed by cytochrome c release. Using glucosyltransferase-deficient 
mutants, Gerhard and his colleagues demonstrated that the activation of caspases and induction of 
apoptosis in human colonic HT29 cells depend on the glucosyltransferase activity of TcdA [17]. In a 
related study, exposure of human umbilical cord vein endothelial cells (HUVEC) to TcdB 10463 
(which inhibits RhoA/Rac1/Cdc42), or to C3 toxin (which inhibits RhoA, B, and C), resulted in 
apoptosis, whereas inactivation of only Rac1/Cdc42 with TcdB-1470 was unable to induce apoptosis, 
suggesting that RhoA inhibition is responsible for apoptosis in endothelial cells [173,174]. 
Glucosyltransferase-independent apoptosis was reported as well. Matarrese and colleagues 
demonstrated  that TcdB causes apoptosis in human epithelial HEp-2 cells by directly acting on 
mitochondria, which does not require the N-terminal Rho-inhibiting activity of the toxin [175]. 
However, the authors treated purified mitochondria with TcdB or the GT fragment, which is not the 
case in cells. Moreover, the purity of the toxins was not demonstrated. It was found that treatment of 
cells with TcdA leads to an accumulation of the toxins at the mitochondria within five min following 
exposure, and this event occurs before detectable glucosylation activity of Rho proteins [151]. 
However, a contrary finding was reported that mitochondrial damage as the initiation of apoptosis 
started after 18–24 h of toxin treatment and was clearly Rho-dependent [18]. Another study compared 
apoptosis induction in HeLa cells by a TcdB fragment containing only GT domain versus the intact 
holotoxin B [19]. Holotoxin B induces apoptosis via activation of caspase 3, whereas the GT domain 
does so in a caspase-independent pathway [19]. The authors concluded that TcdB triggers   
caspase-dependent apoptosis as a result of substrate inactivation and may evoke caspase-independent 
apoptosis due to a second, yet undefined activity of TcdB. However, in this work, GT domain was Toxins 2010, 2  
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either delivered as anthrax lethal toxin chimera or expressed in the cells, which may not mimic the 
finding that only the catalytic domain is cleaved and delivered to the cytosol [176]. 
In addition to apoptosis, necrosis is also likely to contribute to mucosal damage. For instance, TcdA 
has been shown to induce cell necrosis [171,177,178], and toxin-induced proinflammatory mediators 
may trigger epithelial necrotic death as discussed below.  
The roles of transcription factors in C. difficile toxins-induced apoptosis or necrosis were rarely 
described [177,179]. One report described that p38 was involved in both apoptosis and necrosis. 
However, transcription factors may also play protective roles in the host in response to C. difficile 
toxins. Chae et al. reported that IқB-kinase β (IKKβ) deficient mice exhibit a rapid and significant 
increase in intestinal epithelial apoptosis, acute mucosal inflammation, mucosal injury, luminal fluid 
secretion, and bacterial translocation in response to TcdA exposure in mouse ligated ileal loops [180]. 
Therefore, in addition to its roles in regulating secretion of chemokines or other proinflammatory 
events, NF-қB plays an important host mucosal protective role in response to TcdA. Recently, 
Hirota et al. have implicated an innate protective role for hypoxia-inducible factor (HIF-1) in response 
to TcdA [181]. In this report, deletion of intestinal epithelial HIF-1alpha was demonstrated to exhibit 
more severe, toxin-induced intestinal injury and inflammation in mice. In contrast, stabilization of HIF 
with chemicals attenuated toxin-induced injury and inflammation.  
5.3. The role of chemokines released by epithelial cells  
An intense inflammatory response with a marked neutrophil accumulation is a key characteristic of 
the clinical pathophysiology of CDI [182,183]. In animal models, TcdA causes fluid secretion, 
mucosal edema and villus damage by inducing massive acute inflammation with neutrophil 
infiltration [183,184]. The mechanism by which neutrophils are recruited to sites of inflammation is 
a complex and multistep phenomenon that involves the expression of leukocyte and endothelial cell 
adhesion molecules, followed by neutrophil attachment and adhesion to the endothelium, and finally 
transmigration of neutrophils into the intestine mucosa [185]. These events are driven by a local 
production of a wide range of chemoattractants, and by activating cytokines that establish a 
chemotactic gradient and induce the expression of adhesion molecules in both endothelial cells and 
neutrophils. Several molecules are involved in neutrophil recruitment, including IL-8, epithelial 
neutrophil-activating peptide-78 (ENA-78), and the growth-related oncogene (GRO) family in 
humans [186]. Several reports have showed that intestinal epithelial cells can produce chemokine 
IL-8, GRO-α, ENA-78, and monocytes-chemotactic protein (MCP)-1 in response to TcdA 
[21,132,151,183]. IL-8 is a potent proinflammatory chemotactic factor that predominantly exerts 
its effects on neutrophils [187,188]. Interestingly, following intoxication of polarized Caco-2 
colonocytes in a transwell system with TcdA, IL-8 and other chemokines are released predominantly 
into the basolateral compartment [21]. The same phenomenon was also observed by Canny and 
colleagues [137]. Macrophage inflammatory protein (MIP)-2 is the rat homologue of human GRO. 
TcdA induces MIP-2 release from intestinal epithelial cells which contributes to neutrophil 
transmigration in TcdA-induced enteritis [133]. At present, it is not entirely clear how the C. difficile 
toxins induce chemokine or cytokine (see below) production, as is reflected in several conflicting 
publications. Both Rho-dependent and Rho-independent cytokine release mechanisms have been Toxins 2010, 2  
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proposed [177,189,190]. Critical involvement of nuclear factor-κB (NF-κB) or mitogen-activated 
protein kinase p38 in the cytokine secretion has also been described [133,177,191,192]. It will be 
interesting to see whether similarities exist in the signaling pathways initiated by TcdA versus TcdB. 
Certainly, differences have been reported for the two toxins, for example NF-κB is not involved in 
TcdB-mediated IL-8 production, whereas NF-κB plays an important role in TcdA-mediated IL-8 
secretion [151,191]. 
5.4. Immune cells and proinflammatory cytokines/mediators  
In addition to chemokines, release of proinflammatory cytokines or other mediators from immune 
cells seems to be a critical activation event in TcdA-mediated inflammation [25,193]. These 
proinflammatory cytokines are known to exert potent proinflammatory and cytotoxic effects. They 
also mediate septic shock and induce the acute-phase reaction. These mediators may promote 
proinflammatory and cytotoxic effects in the pathophysiological mechanisms of CDI, or they may act 
synergistically with the direct cytopathic effects of TcdA or TcdB. In fact, local release of TNF-α in 
the intestinal mucosa is known to cause cellular alterations, increase intestinal permeability, activate 
endothelial cells, and enhance inflammation [194]. IL-1β was reported to increase both IL-8 secretion 
by HT-29 cells exposed to TcdA, and promote intercellular adhesion molecule-1 (ICAM-1)-dependent 
neutrophil adhesion [135,136]. 
Neutrophil-derived proinflammatory mediators act on epithelial cells, causing destruction and 
necrosis of enterocytes and colonocytes [166]. Neutrophils contribute significantly to tissue damage, 
as these cells contain a potent arsenal of oxidants and proteases in azurophillic granules [25,133]. In 
addition to chemoattractant-induced recruitment of neutrophils in CDI, TcdA also directly interacts 
with neutrophils via a G protein-linked receptor. TcdA directly stimulates human neutrophils, 
promoting a transient increase in intracellular Ca
2+ levels that stimulates neutrophil chemotaxis [25,195]. 
A blocking antibody to CD18, an ICAM-1 ligand in neutrophils, markedly reduces neutrophil 
infiltration in TcdA-exposed rabbit ileal loops [25]. Inhibition of neutrophil recruitment in this model 
is associated with a substantially reduced intestinal permeability, fluid secretion, and mucosal injury. 
Ishida and colleagues reported the essential involvement of IFN-γ in TcdA-induced enteritis [134]. 
Injection of TcdA into mouse ileal loops induces massive fluid secretion, disruption of intestinal 
mucosal integrity with neutrophil infiltration, and production of  IFN-γ, TNF-α, MIP-1 and -2, 
keratinocyte-derived chemokine (KC), and ICAM-1. IFN-γ protein is mainly detected in infiltrating 
neutrophils. In contrast, TcdA-treated IFN-γ knockout mice show marginal histopathological changes 
and cytokine/chemokine gene expression is drastically attenuated. Furthermore, Ishida et al. 
demonstrated that pretreatment of wild type mice with a neutralizing anti-IFN-γ antibody prevents 
TcdA-induced enteritis. Therefore, locally produced IFN-γ may enhance neutrophil transmigration 
directly and/or indirectly by enhancing chemokine and ICAM-1 expression. 
Intestinal mast cells are critically involved in neutrophil activation in TcdA-mediated inflammation. 
Increased mucosal and circulating levels of the specific mucosal  mast cell enzyme, rat mast cell 
protease II (RMCP II), and degranulation of mucosal mast cells are observed within 15–30 min after 
TcdA exposure [107]. Depletion of mast cells significantly diminishes intestinal inflammation after 
TcdA exposure, and is restored following reconstitution of mast cells in mast cell-deficient mice [193]. Toxins 2010, 2  
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In another study,  stabilizing mucosal mast cells with ketotifen reduced the severity of secretory 
diarrhea and inflammation. Ketotifen inhibits TcdA-induced release of mast cell mediators, including 
leukotriene B4 and C4 and RMCP II [140]. Direct effects of TcdA and TcdB on mast cells was shown 
in rat basophilic leukemia (RBL) cells, murine peritoneal mast cells, and more recently in human mast 
cells HMC-1 [196–198].  Moreover, TcdB stimulates HMC-1 cell degranulation and p38   
MAPK-dependent up regulation of IL-8 secretion [198].  
Dendritic cells (DCs) are antigen-presenting cells that play important roles in innate and adaptive 
immune responses [199]. In addition to their role in antigen sampling and processing, DCs are potent 
immune regulatory cells that secrete a vast spectrum of modulating substances including chemokines 
and cytokines [200]. Recently, significant progress has been made in demonstrating that a subset of 
intestinal lamina propria DCs (CD11c
+ and CD11b
+) directly protrudes dendrites crossing epithelial 
barriers into intestinal lumen to sample bacterial antigens [201]. This subset of DCs in the lamina 
propria likely plays an important role in sensing intestinal pathogens and their products. However, the 
role of intestinal DCs in C. difficile toxin-induced intestinal inflammation has not yet been studied, 
although a recent study by Lee and colleagues has reported that TcdA promotes bone marrow-derived 
DC maturation and production of neutrophil-attracting chemokine [202].  
Macrophages play an important role in the pathogenesis of C. difficile-induced colitis [23,203]. In 
the normal colon, intestinal macrophages lie in close proximity to the surface epithelial cells. In 
C. difficile colitis, tissue macrophages may well become exposed to toxins, especially following 
colonic micro-ulceration [29]. Macrophages are key sources of proinflammatory mediators including 
prostaglandins, leukotriene B4, nitric oxide (NO), IL-1β and TNF-α  [204]. Ng et al. reported that 
TcdA and TcdB trigger IL-1β release by macrophages via activating an ASC (apoptosis-associated 
speck-like protein containing a CARD)-containing inflammsome, contributing to toxin-induced 
inflammation and damage in vivo [147]. Macrophages are also a major source of IL-8 [23]. In addition 
to IL-8, both IL-1β and TNF-α are involved in the neutrophil recruitment during CDI [138,139]. In a 
rat model, TcdB induces neutrophil migration via the release of leukotrienes, (notably B4) and TNF-α 
from resident macrophages [138]. Lamina propria macrophages are also activated by substance P (SP), 
releasing TNF-α during acute TcdA-induced intestinal inflammation. Administration of SP receptor 
antagonists diminishes the TNF-α production by lamina propria macrophages isolated from rat   
TcdA-exposed ileal loops [142]. Human monocytes are precursors of tissue macrophages. TcdA and 
TcdB are both able to induce IL-1, IL-6, TNF-α secretion by human monocytes [24]. In addition, 
TcdA can induce IL-8 secretion in peripheral blood monocytes and in the monocyte cell line   
THP-1 [23,132,205]. 
5.5. Role of neuronal cells 
There is clear evidence that primary sensory neurons are also involved in C. difficile toxin-induced 
intestinal inflammatory response. Activation of the sensory nerves and release of sensory 
neuropeptides, including SP and calcitonin gene-related peptide (CGRP), are important in mediating 
and amplifying toxin-induced inflammatory signal [4,26]. Pothoulakis and colleagues demonstrated 
that SP and CGRP are elevated in the cell bodies of spinal cord dorsal root ganglia (DRG) and 
intestinal mucosa following TcdA-exposure of rat ileal loops [142,143]. Administration of capsaicin, a Toxins 2010, 2  
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neurotoxin that desensitizes sensory nerve endings attenuated the toxin response. Moreover, SP 
receptor (i.e.,  NK-1) and CGRP antagonists dramatically reduced TcdA-induced fluid secretion, 
mucosal permeability, and proinflammatory cytokine release [206]. In support of these findings, mice 
lacking NK-1 receptors were substantially desensitized to TcdA-induced enteropathy [207]. Using 
similar approaches this group also demonstrated that neuron peptide Corticotropin-releasing hormone 
(CRH) is required in TcdA mediated intestinal inflammation [208–210]. 
Melanin-concentrating hormone (MCH) is a hypothalamic orexigenic neuropeptide that regulates 
energy balance. Pothoulakis and colleagues found that TcdA induced upregulation of MCH and its 
receptor MCHR1 in the human intestinal xenograft model and of MCHR1 in colonocytes. Treatment 
of colonocytes with MCH upregulates the transcription of IL-8. Moreover, MCH-deficient mice 
develop an attenuated TcdA-mediated intestinal inflammation and secretion [148].  
Neurotensin (NT) is another neuropeptide mediator in TcdA-induced enteritis [144]. NT is a 
peptide primarily synthesized in the brain and GI tract, and its expression is rapidly upregulated 
following toxin-induced enteropathy in the rat. The NT receptors are similarly upregulated by TcdA, 
and NT receptor antagonist inhibits TcdA-induced fluid secretion, mucosal permeability, and   
mast cell activation. Interestingly, NT-mediated degranulation of  mucosal mast cells in vitro is 
inhibited by a SP receptor antagonist, suggesting a functional communication between NT and SP in  
TcdA-mediated enterotoxicity. 
Neunlist et al. investigated the role of human submucosal neurons in TcdB-mediated responses. In 
their experiment setup, isolated segments of human colon were placed in an organ culture for 3 h in the 
presence of TcdB or IL-1β, and whole mounts of internal submucosal plexus were stained with 
antibodies against c-Fos, neuron-specific enolase (NSE), vasoactive intestinal polypeptide (VIP), and 
substance P (SP). The membrane potential (Vm) response of submucosal neurons to the local 
application of toxin B and IL-1β was determined by a multisite optical recording technique. Using this 
unique approach, they found that TcdB activates human VIP-positive submucosal neurons, partially 
via an IL-1β-dependent pathway [145]. Submucosal nervous system was also reported to be involved 
in IL-8 secretion in an IL-1β-dependent manner in TcdB-treated human intestinal tissues [135].  
Further support for a neuronal involvement in CDI is provided by a study demonstrating the 
involvements of protease-activated receptor 2 (PAR2) in TcdA-induced enteropathy [146]. PAR2 
belongs to a family of G protein-coupled receptors that are activated by proteolytic cleavage within 
their extracellular N-terminal domain. Within the intestine, PAR2 is expressed on enterocytes as well 
as on neurons, monocytes, endothelial cells, and neutrophils. Trypsins and tryptase are prominent 
agonists of PAR2 in the gastrointestinal tract. PAR2 activation is associated with pro-inflammatory 
effects, many of which show similarity to those induced by TcdA. In this study, PAR2 deletion or 
pretreatment of rat ileal loops with tryptase inhibitors decreases the TcdA-induced enteropathy. In 
addition, TcdA injection into ileal loops increases the expression of PAR2 and trypsin IV on epithelial 
cells. The authors also showed that tryptase and trypsin isozymes induce ileitis, which can be 
prevented by pretreatment of the ileal loops with NK-1 receptor antagonist. Therefore, PAR2 and its 
activators are proinflammatory in TcdA-induced enteritis and PAR2 causes inflammation through a 
neurogenic mechanism.  
Another potential mediator of neuronal-mediated enteropathy in response to TcdA is leukotriene B4 
(LTB4). Using rat ileal loops, McVey and Vigna showed that TcdA induces LTB4 secretion, a Toxins 2010, 2  
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mediator that can cause a similar ileitis as TcdA [141]. They reported that the inflammatory effects of 
TcdA are blocked by inhibiting LTB4 synthesis, and that the inflammatory effect of LTB4 depends on 
the activation of the transient receptor potential vanilloid (TRPV1). TRPV1 is expressed on   
capsaicin-sensitive primary neuronal afferents of the DRG, and has been shown to partially mediate 
TcdA-induced inflammatory response in the rat intestine. In addition, this group found that LTB4 
stimulates TRPV1-mediated endogenous SP release. Pretreatment of the ileum with NK-1 receptor 
antagonist blocks LTB4-induced SP action and inflammation. Therefore, LTB4 may mediate the 
inflammatory effects of TcdA via activation of TRPV1 receptor and by release of SP. 
5.6. Role of other toxin-induced mediators in CDI 
The acute intestinal inflammatory response to TcdA in animal models (mostly demonstrated in ileal 
loops of mice, rats, and rabbits), have demonstrated a clear role for TcdA in modulating inflammatory 
events. This inflammation is also implicated in the intestinal hyper-secretion and tissue damage. In 
addition to the mediators described above, several other classes of signaling molecules have been 
implicated in CDI.  
5.6.1. Reactive oxygen species (ROS) 
Qiu and colleagues reported that ROS participates in TcdA-induced enteritis in rats [149]. ROS and 
nitric oxide species have been implicated in the pathogenesis of experimental colitis in animal models 
and in idiopathic inflammatory bowel disease of humans. In this study, the authors showed that 
intraluminal TcdA causes a significant increase in hydroxyl radical and hydrogen peroxide production. 
The production of ROS is inhibited by pretreatment with either DMSO, a ROS scavenger, or with 
superoxide dismutase (SOD), an inhibitor of ROS. It appears that the mucosal xanthine oxidase is not 
directly involved in TcdA-associated intestinal response, suggesting ROS released during TcdA 
enteritis is primarily from neutrophils invading in the inflamed bowel segment. ROS involvement in  
TcdA-induced intestinal inflammation is also reported in a more recent study [150]. Moreover, nitric 
oxide species have been shown to play a protective role in TcdA-induced enteritis in rats [211]. Our 
group has recently demonstrated that a component of this nitric oxide based protection against TcdA is 
mediated by S-nitrosothiol intermediates generated during CDI (unpublished findings). The study by 
Hirota et al. has confirmed the importance of nitric oxide signals in protecting against TcdA-induced 
enteropathy, and has implicated NO regulation of HIF in this process. S-nitrosothiols (which are stable 
nitric oxide intermediates) are potent regulators of HIF-1 activity via S-nitrosylation of this 
transcription factor. 
5.6.2. Lipid inflammatory mediators 
Lipid inflammatory mediators are also implicated in the initiation and perpetuation of TcdA-induced 
inflammation. Alcantara et al. demonstrated that inhibition of cyclooxygenase-2 (COX-2) blocks the 
TcdA-induced inflammatory response in rabbit ileal loops [153]. Kim et al. have shown that TcdA 
induces COX-2 expression and releases prostaglandin E2 (PGE2) in a dose- and time-dependent 
manner in cultured human colonocytes and in human intestinal xenografts. The main signaling Toxins 2010, 2  
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pathway for TcdA-induced human COX-2 involves reactive oxygen species (ROS)-mediated 
activation of p38 MAPK, stress-activated protein kinase-1 (MSK-1), COX-2 cAMP-responsive 
element binding protein (CREB), and activating transcription factor 1 (ATF-1) [150]. The conclusion 
was that TcdA triggers ileal inflammation and fluid secretion via induction of COX-2 and release of 
PGE2. In line with this findings, Meyer et al. recently reported that TcdB directly stimulate human 
mast cells to synthesize PGE2/PGD2 (prostaglandin) in a p38 MAPK-dependent pathway [198]. Lima 
and colleagues demonstrated that blocking phospholipase A2 activity, which is involved in the initial 
biochemical synthesis pathway of inflammatory lipid mediators, prevents both the inflammatory 
response and enteropathy induced by TcdA in rabbit ileal loops and in human T-84 cells [212]. 
Platelet-activating factor (PAF) is a phospholipid synthesized and released by several tissues and cells 
such as neutrophils, eosinophils, basophils, mast cells and endothelial cells. PAF is one of the major 
metabolites of acylphospholipid after phospholipase A2 cleavage. In addition, PAF is a potent stimulus 
of phospholipase A2. Fonteles et al. demonstrated that PAF inhibitors are able to decrease the   
hyper-secretion and inflammation, indicating a regulatory role for PAF in TcdA-induced entropathy [155]. 
5.6.3. Na
+/H
+ exchanger (NHE) 
The Na
+/H
+ exchanger (NHE) family consists of eight identified members (NHE1-8), all of which 
are integral membrane proteins that catalyze electro-neutral exchange of alkali cations for H
+. NHE3 is 
expressed in the apical membrane and in subapical endosomes of polarized epithelial cells. In 
intestine, NHE3 is thought to play a critical role in Na
+ absorption and fluid homeostasis [213,214]. 
Recently, Hayashi et al. reported that TcdB causes the disappearance of NHE3 from apical surface in 
cultured epithelial cells, which, in addition to increased paracellular permeability, may also contribute 
to fluid secretion in CDI [156]. TcdB treatment leads to a pronounced inhibition of NHE3 activity, the 
translocation of NHE3 to a subapical endomembrane compartment, and dephosphorylation and 
extensive redistribution of Ezrin. The authors proposed that the inactivation of Rho GTPases by TcdB 
may cause the dissociation between NHE3 and the microvillar cytoskeleton by impairing the ability of 
ezrin to bridge the exchangers to actin, leading to NHE3 internalization and its consequent 
disappearance from the apical surface [156]. 
5.6.4. Angiotensin II 
The renin-angiotensin system (RAS) is a multi-organ system of proteins and receptors that is 
regulated by hormones and cytokines to control a number of mechanisms associated with fluid balance 
and vasoconstriction. Angiotensin II (Ang II) is the main active peptide in the renin-angiotensin 
system. It was known that Ang II was vasoactive, capable of stimulating vascular smooth muscle cells. 
AngII binding to the type 1 receptor (AT1) results in vasoconstriction, and its binding to the type 2 
receptor (AT2) results in vasorelaxation. Both AT1 and AT2 are known to play a major role in the 
cardiovascular and renovascular systems that mediate inflammation, cell growth, and fibrosis. There 
has been considerable interest in the presence of a local angiotensin system in the gastrointestinal tract. 
Alcantara and colleagues investigated the role of Ang II in a rabbit ileal loop model of CDI [157]. 
They showed that Ang II receptor blockers not only inhibit TcdA-induced intestinal hyper-secretion, Toxins 2010, 2  
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but also decrease the production of Ang II in the ileum. This raises the possibility that Ang II may 
participate in a positive feedback loop regulating the hyper-secretory response.  
5.6.5. Epidermal growth factor receptor (EGFR) 
Na  et al. reported that TcdB signals an acute proinflammatory response in colonocytes via 
transactivation of the EGFR and activation of the Erk/MAP kinase pathway [158]. TcdB activates 
EGFR and Erk1/2, leading to their phosphorylation and subsequent IL-8 production by human 
colonocytes. Pretreatment of cells with an EGFR inhibitor or a neutralizing antibody blocks both 
TcdB-induced EGFR and Erk activation. Inhibition of EGFR and Erk activation significantly 
decreases TcdB-induced IL-8 expression. It is also possible that this EGFR activation results from 
inhibition of cellular Src-1 activity mediated by TcdA [169].  
6. Concluding Remarks  
Even though C. difficile infection has a broad spectrum of manifestations, it occurs almost 
exclusively in the large bowel and shows the characteristic microscopic and gross lesions, diarrhea and 
intestinal inflammation. Most of these distinguishing symptoms can be ascribed to inflammatory 
events mediated by TcdA and TcdB. Both TcdA and TcdB induce intestinal injury and inflammation 
through disruption of the intestinal epithelial barrier, induction of proinflammatory mediators and 
causing cell apoptosis or necrosis. Both TcdA and TcdB are glucosyltransferases that irreversibly 
inactivate small Rho GTPases, leading to disruption of cytoskeleton and tight junctions and subsequent 
cell rounding, detachment and cell death. In parallel, intestinal epithelial cells produce chemokines like 
IL-8 and adhesion molecules like ICAM-1, which further lead to the neutrophil adhesion, infiltration, 
and subsequent mucosal inflammation. The compromised mucosal barrier may allow toxins to directly 
act on immune cells and neurons to induce the secretion of proinflammatory cytokines like IL-1β, 
TNF-α, neuropeptides, and many other mediators. In addition, toxins by themselves or synergistically 
with other mediators can activate apoptotic or necrotic pathways in epithelial, immune cells, 
contributing to mucosal damage. All these events produce a complex pathophysiological response 
leading to intestinal inflammation (Figure 2).  
Our understanding of the enterotoxicity of TcdA and TcdB and their mechanisms of action has been 
expanded based on many exciting developments in this field. We can only highlight several pioneering 
work defining our views on C. difficile toxin enterotoxicity. It was recognized for a long time that 
TcdB was a cytotoxin, since purified TcdB alone fails to induce intestinal damage in animal models. 
Our group for the first time demonstrated the enterotoxicity of TcdB in a well designed human 
intestinal xenograft model [20]. Most recently Lyras and colleagues elegantly generated isogenic 
C. difficile strain in which tcdA or tcdB gene was inactivated. They demonstrated that TcdB plays a 
more important role than TcdA in causing CDI in hamsters [30]. In line with this TcdA
−TcdB
+ strains 
have been reported to cause human CDI [90]. While the determination of 3D structures of toxin 
fragments will is helpful to understand the bioactivities of the toxins, the scientists in the field are 
expecting to have high-resolution 3D structure of holotoxins. The identification of the autocatalytic 
cleavage of TcdB is another big stride in advancing our knowledge on the molecular mode of action of 
the toxins [115], which will help to rationalize new therapies targeting toxins’ autocatalytic activity. Toxins 2010, 2  
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Figure 2. Mechanisms of TcdA- and TcdB-mediated enterotoxicity. TcdA and TcdB cause 
intestinal damage and inflammation by direct actions on intestinal epithelial cells, leading 
to chemokine release, cell rounding and apoptosis or necrosis. Alternatively, the toxins 
may target immune cells and neurons once the intestinal epithelial barrier is disrupted. The 
toxins may also act indirectly by stimulating cells to produce chemokine, proinflammatory 
cytokine, neuropeptides, and other mediators. IL-8: interleukin-8; MIP-2: macrophage 
inflammatory protein-2; SP: substance P; CGRP: calcitonin gene-related peptide; NT: 
neurotensin; PAF: Platelet-activating factor; LC4: Leukotriene C4; ROS: Reactive   
oxygen species.  
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Despite the progress that we have made in understanding the molecular mode of action of the two 
toxins, many fundamental questions remain unanswered. Are there specific receptors for TcdA and 
TcdB? And if so, what are they? Why do TcdA and TcdB differ considerably with respect to their 
biological activities while they share high sequences homology and similar domain structures, and act 
in a similar molecular mode? What are the respective roles of these two toxins in the host 
inflammatory response and pathogenesis? Given the increasing importance of CDI in public health, 
significant more research is necessary to fill these gaps in our knowledge in order to better tackle 
the disease.  Toxins 2010, 2  
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